Cefazolin EP Impurity C

Embryo and developmental toxicity of cefazolin sodium impurities in zebrafish
By Chen, Bo; Gao, Zhu-Qing; Liu, Ying; Zheng, Yang-Min; Han, Ying; Zhang, Jing-Pu; Hu, chang-Qin
From Frontiers in Pharmacology (2017), 8, 403/1-403/13
 
Stability of cefazolin sodium for injection in different solvents
By Peng, Yan; Zhang, Ling-li; Shen, Bing-zheng; Wu, Yue; Zhou, Ding-shan; Song, Jin-chun
From Xiandai Yaowu Yu Linchuang (2014), 29(7), 813-817
 
Comparison study of impurity contents of cefazolin sodium pentahydrate and cefazolin sodium
By Chen, Yong-gang; Ma, Chuan-xue; Yang, Qing; Liu, Xiao-ling; Li, Fan; Lu, Xiang; Sun, Yuan-feng
From Zhongguo Yaofang (2013), 24(25), 2383-2386
 

Cefazolin EP Impurity C is chemically (6R,7R)-3-Methyl-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (as per EP); (6R,7R)-7-(2-(1H-tetrazol-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (as per USP) . It is also known as Cefazolin 3-Methyl Analog (USP). Cefazolin EP Impurity C is supplied with detailed characterization data compliant with regulatory guideline. Cefazolin EP Impurity C can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Cefazolin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.